Biospain 2023: Oryzon Genomics y Vive Biotech

from Biotecnología Capital · host Capital Radio

Con el director científico de Oryzon, Jordi Xaus, analizamos sus avances con su molécula para enfermedades del sistema nervioso. El CEO de Vive, Gurutz Lizanasoro, nos explica el objetivo de la compañía con sus vectores virales.

Episode metadata supplied by the publisher feed · Published Feb 10, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Biospain 2023: Oryzon Genomics y Vive Biotech

0:00 22:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Biotecnología Capital?

This episode is 22 minutes long.

When was this Biotecnología Capital episode published?

This episode was published on February 10, 2023.

Can I download this Biotecnología Capital episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!